Shineco's Subsidiary InfiniClone Partners with Total World Marketing for Entry into the Southeast Asian Healthcare Market
MWN-AI** Summary
Shineco, Inc. (NASDAQ: SISI) has announced a strategic partnership between its majority-owned subsidiary InfiniClone Limited and Total World Marketing (TWM) in Thailand, marking a significant step in its expansion into the Southeast Asian healthcare market. This collaboration aims to promote and sell InfiniClone's molecular detection kits and Purelix health products in the region. The partnership aligns with Shineco's broader globalization strategy, targeting a rapidly growing healthcare consumer market in Southeast Asia.
The Southeast Asian market is on an upward trajectory, with a notable 25% year-over-year increase in healthcare product sales via leading e-commerce platforms Shopee and Lazada, reaching $1.57 billion in 2023. The rising consumer purchasing power, increased health awareness, and economic recovery post-pandemic are driving demand for innovative healthcare solutions.
InfiniClone's molecular detection kit utilizes advanced induced pluripotent stem cell (iPSC) technology to analyze genetic diseases and offer insights for personalized health management. Complementing this, the Purelix product line provides immune enhancement and other health solutions based on the results from the detection kit, creating a "detection-intervention" system for consumers.
Dr. Lim Kah Meng, the founder of InfiniClone, expressed optimism about TWM's supermarket presence enhancing initial market penetration, with plans to eventually expand into pharmacies, clinics, and e-commerce channels pending regulatory approvals. Shineco's CEO, Jennifer Zhan, underscored the company’s commitment to integrating R&D, production, and distribution efforts in Southeast Asia, aiming to leverage TWM’s distribution capabilities.
In conclusion, this partnership represents Shineco's strategic initiative to enhance its market presence in Southeast Asia's burgeoning healthcare sector, focusing on innovative, technology-driven health solutions that cater to the rising consumer demand.
MWN-AI** Analysis
The partnership between Shineco's subsidiary InfiniClone and Total World Marketing (TWM) marks a significant step in the healthcare market expansion strategy for Southeast Asia, a region witnessing remarkable growth in healthcare consumer products. With e-commerce sales reaching $1.57 billion in 2023 and a projected increase in consumer purchasing power, the timing is ripe for new entrants like InfiniClone.
Investors should note that InfiniClone's product line, comprising molecular detection kits and the Purelix series health products, utilizes advanced iPSC technology to address various health conditions, including diabetes and cancer. This innovation positions the company well within a highly competitive healthcare landscape that benefits from increased health awareness post-pandemic.
The collaboration with TWM, focusing on channels like supermarkets, pharmacies, and e-commerce platforms, aligns strategically with current consumer behavior favoring convenience and accessibility in health products. As regulatory approvals are sought for InfiniClone’s detection kits, managing these logistical steps will be critical to the smooth rollout of operations and ultimately to corporate profitability.
A potential opportunity exists in InfiniClone's plan for a "detection-intervention" system—a holistic approach to personalized health management which could significantly enhance lifetime customer value as it addresses immediate and ongoing health concerns.
Investors looking to engage with Shineco should evaluate the stock’s growth potential driven by this collaboration alongside broader industry dynamics, such as the increasing emphasis on personalized medicine and preventative healthcare solutions. Monitoring regulatory developments and consumer response in initial market penetrations will be essential. An investment in Shineco could align well with those seeking exposure in a sector poised for expansion, but investors should remain cognizant of inherent risks in biopharma and healthcare product launches.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BEIJING, May 13, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced that InfiniClone Limited ("InfiniClone"), Shineco's majority-owned subsidiary in which the Company acquired a 51% equity interest on April 25, 2025, has officially launched its Southeast Asian market expansion strategy as it has reached a strategic distribution agreement with Total World Marketing (Thailand) ("TWM"), pursuant to which TWM will be responsible for the promotion and sale of InfiniClone’s molecular detection kits and InfiniClone’s Purelix series health products in the Southeast Asian market. Shineco believes that this marks a key step in its globalization strategy to develop robust market positioning in the healthcare products and services sector.
The healthcare consumer market in Southeast Asia is experiencing dynamic growth. As an indicator, Moojing Market Intelligence, a Chinese market research and intelligence firm, states that the sales of healthcare products by Shopee and Lazada, the two major e-commerce platforms in Southeast Asia, reached $1.57 billion in 2023, a year-over-year increase of more than 25%. The region’s economic recovery, increased consumer purchasing power and enhanced health awareness in the post-epidemic era have driven the continued rise in demand for a broad range of healthcare products including precision diagnostic products.
InfiniClone’s molecular detection kit is based on its core iPSC technology, and it is designed to analyze genetic mutations for diseases including diabetes, cancer, Alzheimer's disease, as well as genetic characteristics such as drug response, skin characteristics, and nutritional metabolism; the kit is expected to provide consumers with a firm basis for personalized health management. InfiniClone’s Purelix health products are designed to customize immune enhancement, brain nerve support and antioxidant solutions based on InfiniClone’s molecular detection kit test results, and Purelix dietary supplements can also achieve symptomatic relief. The Company expects the two major product lines to form a "detection-intervention" closed-loop system to help consumers understand their health profiles and help them address certain medical issues.
Dr. Lim Kah Meng, founder of InfiniClone, commented, "The breakthrough application of our iPSC technology serves as the basis for the accuracy of InfiniClone’s two products, and we anticipate TWM's extensive coverage in supermarket channels will provide a solid foundation for our initial market penetration. Looking forward, we plan to further deepen the coverage dimension of disease risk prediction and explore the application of our iPSC technology in the field of tissue repair and anti-aging to provide more comprehensive health solutions for the Southeast Asian market."
TWM has currently launched a pilot sale of InfiniClone’s Purelix health products through supermarket channels in Thailand, and it plans to expand next month into multiple sales channels such as pharmacies, clinics and e-commerce platforms after obtaining approval from the Thai Food and Drug Administration for InfiniClone’s molecular detection kits. In addition, InfiniClone is negotiating with a number of medical institutions in Southeast Asia to explore the clinical application of molecular detection kits in early disease screening and treatment monitoring.
Jennifer Zhan, the CEO of Shineco, emphasized, "We believe the recent acquisition of InfiniClone has not only improved our competitive positioning, but it is also helping us to develop an integrated network of 'R&D-production-distribution' centered on Southeast Asia. The cooperation between InfiniClone and TWM is being developed in a phased strategy, initially focusing on supermarket channels to obtain market feedback and gradually expanding in conjunction with the progress of regulatory approval.”
“By integrating TWM's channel resources with InfiniClone's R&D advantages, we are confident that we will be able to quickly respond to Southeast Asian market demand. We also plan to accelerate the application and transformation of stem cell technology in the field of big health, which encompasses the spectrum of prevention, wellness and technology-driven solutions. InfiniClone's product line aligns exceptionally well with the high-growth trajectory of big health, a pivotal strategy that we believe will generate considerable benefits for Shineco and create long-term value for our shareholders," CEO Ms. Zhan concluded.
About InfiniClone
InfiniClone is a biotech company based in Singapore and controlled by Shineco. It is an innovative enterprise focusing on induced pluripotent stem cell (iPSC) technology and regenerative medicine. For more information about InfiniClone, please visit www.infiniclone.com/ .
About Shineco, Inc.
Shineco, Inc. ("Shineco" or the "Company") aims to "focus on healthy living and improve the quality of life" by providing safe, efficient and high-quality health and medical products and services to society. Shineco, operating through subsidiaries, has researched and developed 33 kinds of in vitro diagnostic reagents and related medical devices to date, and the Company also produces and sells healthy and nutritious foods. For more information about Shineco, please visit www.biosisi.com/ .
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as "may," "will," "should," "could," "intend," "expect," "plan," "budget," "forecast," "anticipate," "believe," "estimate," "forecast," "potential," "continue," "evaluate" or similar words. Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions. Examples of forward-looking statements include, among other things, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake. Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company's ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, Companies to be acquired, Successful integration of technology and assets into its portfolio of products and services Marketing and other business development initiatives Industry competition, general government regulations, economic conditions, impact of the COVID-19 pandemic, reliance on key personnel, attracting, hiring and retaining personnel with the technical skills and experience required to meet customer requirements and protect intellectual property. Shineco encourages you to review other factors that may affect its future performance in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and are made only as of the date of this press release, and Shineco undertakes no obligation to update any forward-looking statements, except as required by applicable rules and regulations.
For more information, please contact:
Shineco, Inc.
secretary@shineco.tech
Mobile: +86-010-68130220
Precept Investor Relations LLC
David J. Rudnick
david.rudnick@preceptir.com
Mobile: +1-646-694-8538
FAQ**
How does Shineco Inc. SISI plan to leverage its 5ownership of InfiniClone to enhance its competitive positioning in the Southeast Asian healthcare market?
What specific metrics will Shineco Inc. SISI use to evaluate the success of the distribution agreement with Total World Marketing in promoting InfiniClone’s products?
Considering the projected growth in the Southeast Asian healthcare market, how does Shineco Inc. SISI anticipate adapting its product offerings to meet evolving consumer demands?
What steps is Shineco Inc. SISI taking to ensure timely regulatory approval for its molecular detection kits in Southeast Asia, and how will that impact its expansion strategy?
**MWN-AI FAQ is based on asking OpenAI questions about Shineco Inc. (NASDAQ: SISI).
NASDAQ: SISI
SISI Trading
-18.91% G/L:
$5.53 Last:
24,594 Volume:
$5.78 Open:
